Dynavax Technologies Corporation (NASDAQ:DVAX) – Investment analysts at William Blair upped their FY2017 earnings per share estimates for Dynavax Technologies Corporation in a research report issued on Monday. William Blair analyst Y. Xu now expects that the biopharmaceutical company will post earnings of ($1.71) per share for the year, up from their previous estimate of ($1.73). William Blair has a “Outperform” rating and a $30.00 price objective on the stock. William Blair also issued estimates for Dynavax Technologies Corporation’s Q4 2017 earnings at ($0.35) EPS, Q1 2018 earnings at ($0.25) EPS, Q2 2018 earnings at ($0.19) EPS, Q3 2018 earnings at ($0.12) EPS, Q4 2018 earnings at ($0.02) EPS, FY2018 earnings at ($0.59) EPS and FY2019 earnings at $0.91 EPS.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies Corporation had a negative net margin of 1,177.60% and a negative return on equity of 80.40%. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.28 million. During the same period last year, the company posted ($0.90) EPS. The company’s revenue was down 68.8% on a year-over-year basis.

WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/fy2017-eps-estimates-for-dynavax-technologies-corporation-dvax-lifted-by-william-blair/1687442.html.

DVAX has been the topic of several other research reports. Royal Bank Of Canada set a $7.00 price target on shares of Dynavax Technologies Corporation and gave the stock a “hold” rating in a research note on Wednesday, July 26th. Zacks Investment Research downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Cowen and Company reissued an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies Corporation in a research report on Thursday, August 10th. Cantor Fitzgerald initiated coverage on shares of Dynavax Technologies Corporation in a research report on Friday, September 15th. They issued an “overweight” rating and a $24.00 target price for the company. Finally, ValuEngine raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Dynavax Technologies Corporation presently has an average rating of “Buy” and an average target price of $25.00.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) opened at $21.43 on Wednesday. Dynavax Technologies Corporation has a 12 month low of $3.20 and a 12 month high of $24.45.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE boosted its holdings in shares of Dynavax Technologies Corporation by 2.3% during the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares during the period. Nationwide Fund Advisors boosted its holdings in Dynavax Technologies Corporation by 2.5% in the 2nd quarter. Nationwide Fund Advisors now owns 28,359 shares of the biopharmaceutical company’s stock valued at $274,000 after purchasing an additional 692 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in Dynavax Technologies Corporation by 3.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock valued at $162,000 after purchasing an additional 939 shares during the period. American International Group Inc. raised its stake in shares of Dynavax Technologies Corporation by 7.1% in the 1st quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 1,584 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC raised its stake in shares of Dynavax Technologies Corporation by 16.5% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 1,700 shares in the last quarter. 59.84% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Earnings History and Estimates for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.